IVA Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in F…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading European equities traded in the US as American depositary receipts were lower on Tuesday morning, de | ||
 Inventiva (IVA) Q2 2026 Earnings Call Transcript Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027. | ||
Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ... Inventiva SA (IVEVF) reported EUR233.9 million in cash and reaffirmed Q4 2026 top-line NATIV3 data for its MASH therapy lanifibranor, keeping a potential NDA submission on track for H1 2027. | ||
 Inventiva Q2 Earnings Call Highlights Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study’s 72-week visit earlier this month. Chie | ||
 Chris Benecchi Named Inventiva’s New Chief Operating Officer By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge. | ||
 Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring Inventiva S.A. (NASDAQ:IVA) is one of the best strong buy penny stocks to invest in now. Inventiva S.A. (NASDAQ:IVA) announced on July 9 the completion of the final step of the transactions previously announced on June 2, 2026, through the issuance of approximately 15.7 million new warrants to the European Investment Bank, along with the […] | ||
 Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound Inventiva (ENXTPA:IVA) stock has been relatively flat in the latest session, leaving investors focused on how its clinical stage pipeline in MASH and rare diseases, together with recent share performance, shapes the current risk reward profile. See our latest analysis for Inventiva. Over the past year, Inventiva’s share price return has been mixed, with a 9.1% 1 month gain and a 15.4% decline over 3 months. The 1 year total shareholder return of 34.7% points to earlier buying interest that... | ||
European Equities Traded in the US as American Depositary Receipts Rise Thursday European equities traded in the US as American depositary receipts were rising on Thursday morning, | ||